Manager
GESIURIS ASSET MANAGEMENT, SGIIC, S.A.
See the CNMV manager universe →
Fund page
GESIURIS IURISFOND, FI
Category
—
Latest period
H2 2025
Positions
68
Portfolio as of 2025-12-31. Source: periodic filing with the CNMV. View original filing (PDF)
Full portfolio
Every position in the latest periodic filing, largest weight first. Aggregates ("other equities...") are baskets of small positions the filing itself does not break out line by line.
68
Company
Type
Country
Weight
Price
This period's moves
H2 2025 vs H1 2025 (estimated)
New: 32
Exits: 19
Increases: 6
Cuts: 17
+ ACCIONES|GRIFOLS
Enters the portfolio at 1.02% weight.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
View company page →+ ACCIONES|DEUTSCHE BOERSE AG
Enters the portfolio at 0.55% weight.
Deutsche Börse AG operates as an international exchange organization in Germany, rest of Europe, the United States, and the Asia-Pacific. The company operates through four segments: Investment Management Solutions, Trading & Clearing, Fund Services, and Securities Services. The Investment Management Solutions segment offers financial data, analytics, and software-as-a-service solutions including research, data collection, data analysis, and the provision of indices, analytics and investment management software to institutional investors, banks, and corporate clients. The Trading & Clearing segment engages in the development and operation of markets and trading systems for securities, derivatives, commodities, currencies, digital assets, and other asset classes. This segment handles settlement of transactions through clearing houses. Its Fund Services segment provides infrastructure and services for fund processing, including order routing, settlement, custody, data and distribution support for investment funds. The Securities Services segment offers various services for securities issuance, settlement, custody as well as collateral, securities lending, and liquidity management. The company was founded in 1585 and is headquartered in Eschborn, Germany.
View company page →− INMOB.COLONIAL, S.A.
Leaves the portfolio; it was 3.51% of weight.
− AT&T INC
Leaves the portfolio; it was 2.74% of weight.
− CITIGROUP INC
Leaves the portfolio; it was 2.72% of weight.
− BANK OF AMERICA
Leaves the portfolio; it was 2.69% of weight.
− MEDTRONIC GBLHOLDING
Leaves the portfolio; it was 2.69% of weight.
− NESTLE HOLDING INC
Leaves the portfolio; it was 2.28% of weight.
− PORSCHE
Leaves the portfolio; it was 1.88% of weight.
− REPSOL INTL FINANCE
Leaves the portfolio; it was 1.81% of weight.
− PROSEGUR CASH
Leaves the portfolio; it was 1.80% of weight.
− RYANAIR HOLDINGS PLC
Leaves the portfolio; it was 1.79% of weight.
− ACCIONA
Leaves the portfolio; it was 1.75% of weight.
− ACCIONES|REPSOL SA
Leaves the portfolio; it was 1.47% of weight.
− ACCIONES|JOHNSON & JOHNSON
Leaves the portfolio; it was 0.94% of weight.
− ABERTIS
Leaves the portfolio; it was 0.90% of weight.
− VIDRALA SA
Leaves the portfolio; it was 0.90% of weight.
− METROVACESA
Leaves the portfolio; it was 0.90% of weight.
− ACCIONA
Leaves the portfolio; it was 0.90% of weight.
− CIE AUTOMOTIVE SA
Leaves the portfolio; it was 0.90% of weight.
− GLOBAL DOMINION
Leaves the portfolio; it was 0.88% of weight.
▲ ACCIONES|GSK PLC
Goes from 0.72% to 0.98%.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
View company page →Fixed income
Declared FI exposure
11.6 M €
% of portfolio
71.5%
Positions
44
Issuers
37
Sovereign: 0 €
Corporate: 11.6 M €
Maturity ladder
Observed contractual maturity of each position, repos excluded. Matured/≤3 months includes bonds maturing in the first days after the period close.
Matured or ≤3 months · 3.4%3-6 months · 5.1%6-12 months · 17.7%1-2 years · 37.4%2-5 years · 36.4%
Maturity
Positions
Exposure
%
Matured or ≤3 months
4
390,274 €
3.4%
3-6 months
4
591,664 €
5.1%
6-12 months
10
2.1 M €
17.7%
1-2 years
11
4.4 M €
37.4%
2-5 years
15
4.2 M €
36.4%
5-10 years
0
0 €
0.0%
> 10 years
0
0 €
0.0%
Unknown
0
0 €
0.0%
Top issuers
The 10 issuers with the largest declared exposure in this fund, repos excluded.
Issuer
Type
ISINs
Exposure
Next maturity
BNP PARIBAS SA
Corporate
2
806,841 €
2027-01-23
IBM CORP
Corporate
1
688,749 €
2027-01-29
MOODY´S CORP
Corporate
2
657,161 €
2027-03-09
L´OREAL SA
Corporate
1
501,136 €
2027-11-06
NETFLIX INC
Corporate
2
491,181 €
2026-11-15
TOTALENER CAPITAL SA
Corporate
1
489,429 €
2027-03-04
ENGIE
Corporate
1
481,618 €
2027-06-21
DANONE SA
Corporate
1
412,829 €
2029-11-13
ARCELOR MITTAL
Corporate
1
412,646 €
2026-09-26
COCA-COLA HBC FINANC
Corporate
1
406,061 €
2028-02-27
Top instruments
The 10 instruments with the largest declared exposure. No yield, IRR or rating: there's no reliable data to compute them.
ISIN
Coupon
Maturity
Exposure
XS1945110606 IBM CORP
1.25%
2027-01-29
688,749 €
FR001400TT34 L´OREAL SA
2.50%
2027-11-06
501,136 €
XS1874122770 TOTALENER CAPITAL SA
1.02%
2027-03-04
489,429 €
FR0013428489 ENGIE
0.38%
2027-06-21
481,618 €
FR001400LY92 DANONE SA
3.71%
2029-11-13
412,829 €
XS2537060746 ARCELOR MITTAL
4.88%
2026-09-26
412,646 €
FR001400CFW8 BNP PARIBAS SA
3.63%
2029-09-01
407,891 €
XS2757515882 COCA-COLA HBC FINANC
3.38%
2028-02-27
406,061 €
XS1821883102 NETFLIX INC
3.63%
2027-05-15
405,636 €
XS2790333616 MORGAN STANLEY
2.70%
2027-03-19
400,371 €
Currencies
Fixed-income exposure by instrument currency.
Currency
Exposure
%
EUR
11.4 M €
97.7%
USD
264,649 €
2.3%
This period's fixed-income moves
Compares the current fixed-income portfolio with the previous period, by ISIN. An exit that coincides with maturity isn't a sale: the bond reached its contractual date.
New positions: 25
Exits at maturity: 14
Exits not explained by maturity: 3
+ IBM CORP
Enters the portfolio at 4.24% weight.
+ L´OREAL SA
Enters the portfolio at 3.08% weight.
+ TOTALENER CAPITAL SA
Enters the portfolio at 3.01% weight.
+ COCA-COLA HBC FINANC
Enters the portfolio at 2.50% weight.
+ INMOB.COLONIAL, S.A.
Enters the portfolio at 2.37% weight.
+ ABERTIS
Enters the portfolio at 1.92% weight.
+ ENEL SPA
Enters the portfolio at 1.91% weight.
+ GOLDMAN SACHS
Enters the portfolio at 1.84% weight.
+ GRIFOLS
Enters the portfolio at 1.83% weight.
+ MOODY´S CORP
Enters the portfolio at 1.83% weight.
+ CAIXABANK SA
Enters the portfolio at 1.24% weight.
+ PROSEGUR CASH
Enters the portfolio at 1.20% weight.
+ ACCIONA
Enters the portfolio at 1.20% weight.
+ ACCIONA
Enters the portfolio at 1.20% weight.
+ CIE AUTOMOTIVE SA
Enters the portfolio at 1.20% weight.
+ MASTERCARD INC
Enters the portfolio at 1.16% weight.
+ DEERE & CO
Enters the portfolio at 1.10% weight.
+ METROVACESA
Enters the portfolio at 0.61% weight.
+ AFRICAN DEVELOPMENT
Enters the portfolio at 0.61% weight.
+ GLOBAL DOMINION
Enters the portfolio at 0.61% weight.
+ GLOBAL DOMINION
Enters the portfolio at 0.60% weight.
+ CIE AUTOMOTIVE SA
Enters the portfolio at 0.60% weight.
+ GESTAMP AUTOMOCION S
Enters the portfolio at 0.60% weight.
+ DIAGEO CAPITAL BV
Enters the portfolio at 0.57% weight.
+ NETFLIX INC
Enters the portfolio at 0.53% weight.
− CITIGROUP INC
Leaves the portfolio; it was 2.72% of weight.
− BANK OF AMERICA
Leaves the portfolio; it was 2.69% of weight.
− PORSCHE
Leaves the portfolio; it was 1.88% of weight.
◦ INMOB.COLONIAL, S.A.
Leaves the portfolio; it was 3.51% of weight.
◦ AT&T INC
Leaves the portfolio; it was 2.74% of weight.
◦ MEDTRONIC GBLHOLDING
Leaves the portfolio; it was 2.69% of weight.
◦ NESTLE HOLDING INC
Leaves the portfolio; it was 2.28% of weight.
◦ REPSOL INTL FINANCE
Leaves the portfolio; it was 1.81% of weight.
◦ PROSEGUR CASH
Leaves the portfolio; it was 1.80% of weight.
◦ RYANAIR HOLDINGS PLC
Leaves the portfolio; it was 1.79% of weight.
◦ ACCIONA
Leaves the portfolio; it was 1.75% of weight.
◦ ABERTIS
Leaves the portfolio; it was 0.90% of weight.
◦ VIDRALA SA
Leaves the portfolio; it was 0.90% of weight.
◦ METROVACESA
Leaves the portfolio; it was 0.90% of weight.
◦ ACCIONA
Leaves the portfolio; it was 0.90% of weight.
◦ CIE AUTOMOTIVE SA
Leaves the portfolio; it was 0.90% of weight.
◦ GLOBAL DOMINION
Leaves the portfolio; it was 0.88% of weight.
Disclaimer
This is not financial advice. The portfolio comes from the periodic report the fund files with the CNMV and lags the real close of the period: it is a snapshot of the end of each half-year, not a real-time portfolio.